Acorda Therapeutics Incorporated (NASDAQ:ACOR) Shorted Shares Decreased By 2.9%


The stock of Acorda Therapeutics Incorporated (NASDAQ:ACOR) registered a decrease of 2.9% in short interest. ACOR’s total short interest was 5.55M shares in September as published by FINRA. Its down 2.9% from 5.72M shares, reported previously. With 448,400 shares average volume, it will take short sellers 12 days to cover their ACOR’s short positions. The short interest to Acorda Therapeutics Incorporated’s float is 14.45%. About 94,253 shares traded hands. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 29.90% since February 8, 2016 and is downtrending. It has underperformed by 46.39% the S&P500.

Acorda Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $1.18 billion. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. It currently has negative earnings. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.

The institutional sentiment decreased to 1.13 in 2016 Q2. Its down 0.28, from 1.41 in 2016Q1. The ratio worsened, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.

Ghost Tree Capital Llc holds 2.39% of its portfolio in Acorda Therapeutics Inc for 325,000 shares. Armistice Capital Llc owns 232,000 shares or 2.25% of their US portfolio. Moreover, Deerfield Management Co has 1.03% invested in the company for 1.03 million shares. The New York-based Baker Bros. Advisors Lp has invested 0.98% in the stock. Arbor Capital Management Llc, a Minnesota-based fund reported 58,783 shares.

Out of 2 analysts covering Acorda Therapeutics Inc. (NASDAQ:ACOR), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Acorda Therapeutics Inc. has been the topic of 2 analyst reports since January 6, 2016 according to StockzIntelligence Inc. Goldman Sachs initiated the stock on March 30 with “Neutral” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply